Chemoprevention of colorectal cancer: Slow, steady progress

Article Type
Changed
Mon, 11/05/2018 - 08:02
Display Headline
Chemoprevention of colorectal cancer: Slow, steady progress
Article PDF
Author and Disclosure Information

Carol A. Burke, MD
Department of Gastroenterology, The Cleveland Clinic

William M. Bauer, MD
Glen Falls Hospital, Glen Falls, New York

Bret Lashner, MD
Department of Gastroenterology, The Cleveland Clinic

Address: Carol A. Burke, MD, Department of Gastroenterology, A30, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; email: burkec1@ccf.org

Dr. Burke has indicated that she has received grant or research support from Merck and Co.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Issue
Cleveland Clinic Journal of Medicine - 70(4)
Publications
Topics
Page Number
346-350
Sections
Author and Disclosure Information

Carol A. Burke, MD
Department of Gastroenterology, The Cleveland Clinic

William M. Bauer, MD
Glen Falls Hospital, Glen Falls, New York

Bret Lashner, MD
Department of Gastroenterology, The Cleveland Clinic

Address: Carol A. Burke, MD, Department of Gastroenterology, A30, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; email: burkec1@ccf.org

Dr. Burke has indicated that she has received grant or research support from Merck and Co.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Author and Disclosure Information

Carol A. Burke, MD
Department of Gastroenterology, The Cleveland Clinic

William M. Bauer, MD
Glen Falls Hospital, Glen Falls, New York

Bret Lashner, MD
Department of Gastroenterology, The Cleveland Clinic

Address: Carol A. Burke, MD, Department of Gastroenterology, A30, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; email: burkec1@ccf.org

Dr. Burke has indicated that she has received grant or research support from Merck and Co.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Article PDF
Article PDF
Issue
Cleveland Clinic Journal of Medicine - 70(4)
Issue
Cleveland Clinic Journal of Medicine - 70(4)
Page Number
346-350
Page Number
346-350
Publications
Publications
Topics
Article Type
Display Headline
Chemoprevention of colorectal cancer: Slow, steady progress
Display Headline
Chemoprevention of colorectal cancer: Slow, steady progress
Sections
Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

What is the optimal strategy for colon cancer surveillance in patients with ulcerative colitis?

Article Type
Changed
Mon, 03/11/2019 - 08:09
Display Headline
What is the optimal strategy for colon cancer surveillance in patients with ulcerative colitis?
Article PDF
Author and Disclosure Information

William M. Bauer, MD
Center for Inflammatory Bowel Disease, Department of Gastroenterology, Cleveland Clinic

Bret A. Lashner, MD, MPH
Director, Center for Inflammatory Bowel Disease, Department of Gastroenterology, Cleveland Clinic

Issue
Cleveland Clinic Journal of Medicine - 66(5)
Publications
Page Number
273, 277
Sections
Author and Disclosure Information

William M. Bauer, MD
Center for Inflammatory Bowel Disease, Department of Gastroenterology, Cleveland Clinic

Bret A. Lashner, MD, MPH
Director, Center for Inflammatory Bowel Disease, Department of Gastroenterology, Cleveland Clinic

Author and Disclosure Information

William M. Bauer, MD
Center for Inflammatory Bowel Disease, Department of Gastroenterology, Cleveland Clinic

Bret A. Lashner, MD, MPH
Director, Center for Inflammatory Bowel Disease, Department of Gastroenterology, Cleveland Clinic

Article PDF
Article PDF
Related Articles
Issue
Cleveland Clinic Journal of Medicine - 66(5)
Issue
Cleveland Clinic Journal of Medicine - 66(5)
Page Number
273, 277
Page Number
273, 277
Publications
Publications
Article Type
Display Headline
What is the optimal strategy for colon cancer surveillance in patients with ulcerative colitis?
Display Headline
What is the optimal strategy for colon cancer surveillance in patients with ulcerative colitis?
Sections
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Hide sidebar & use full width
render the right sidebar.
Article PDF Media